Abstract
DNA methylation is essential for normal embryonic development. Distinctive genomic methylation patterns must be formed and maintained with high fidelity to ensure the inactivities of specific promoters during development. The mutagenic and epigenetic aspects of DNA methylation are especially interesting because they may lead to the inactivation of genes which are involved in human carcinogenesis. The mutagenicity of 5-Methylcytosine (5mC) and the role of promoter hypermethylation in gene silencing, particularly in cancer, suggest a clinical significance for the design of novel DNA methylation inhibitors which may be utilized to reverse the effects of DNA methylation.
Similar content being viewed by others
REFERENCES
M. Gardiner-Garden and M. Frommer. CpG islands in vertebrate genomes. J. Mol. Biol. 196:261–282 (1987).
A. P. Bird. CpG-rich islands and the function of DNA methylation. Nature 321:209–213 (1986).
B. K. Duncan and J. H. Miller. Mutagenic deamination of cytosine residues in DNA. Nature 287:560–561 (1980).
T. H. Bestor and G. L. Verdine. DNA methyltransferases. Curr. Opin. Cell Biol. 6:380–389 (1994).
R. J. Roberts. On base flipping. Cell 82:9–12 (1995).
G. L. Verdine. The flip side of DNA methylation. Cell 76:197–200 (1994).
Y. Gruenbaum, H. Cedar, and A. Razin. Substrate and sequence specificity of a eukaryotic DNA methylase. Nature 295:620–622 (1982).
T. H. Bestor and V. M. Ingram. Two DNA methyltransferases from murine erythroleukemia cells: purification, sequence specificity, and mode of interaction with DNA. Proc. Natl. Acad. Sci. USA 80:5559–5563 (1983).
G. P. Pfeifer, S. Grunwald, T. L. J. Boehm, and D. Drahovsky. Isolation and characterization of DNA cytosine 5-methyltransferase from human placenta. Biochem. Biophy. Acta 740:323–330 (1983).
H. Lei, S. P. Oh, M. Okano, R. Jutterman, K. A. Gross, R. Jaenisch, and E. Li. De novo cytosine methyltransferase activities in mouse embryonic stem cells. Development 122:3195–3205 (1996).
A. Razin and A. D. Riggs. DNA methylation and gene function. Science 210:604–610 (1980).
D. Jahner, H. Stuhlman, C. L. Stewart, K. Harbers, J. Lohler, L. Simon, and R. Jaenisch. De novo methylation and expression of retroviral genomes during mouse embryogenesis. Nature 298:623–628 (1982).
M. Monk, M. Boubelik, and S. Lehnert. Temporal and regional changes in DNA methylation in the embryonic, extraembryonic, and germ cell lineages during mouse embryo development. Development 99:371–382 (1987).
A. Razin and H. Cedar. DNA methylation and embryogenesis. In J. P. Jost and H. P. Saluz (eds.) DNA methylation: Molecular biology and biological significance. Basel Switzerland, Birkhauser Verlag, pp. 343.
D. N. Cooper and H. Y. Youssouffian. The CpG dinucleotide and human genetic disease. Hum. Genet. 78:151–155 (1988).
J. C. Shen, W. M. Rideout III, and P. A. Jones. The rate of hydrolytic deamination of 5-methylcytosine in double-stranded DNA. Nucleic Acids Res. 22:972–976 (1994).
C. Lengauer, K. W. Kinzler, and B. Vogelstein. DNA methylation and genetic instability in colorectal cancer cells. Proc. Natl. Acad. Sci. USA 94:2545–2550 (1997).
P. A. Jones, W. M. Rideout, J. C. Shen, C. H. Spruck, and Y. C. Tsai. Methylation, mutation, and cancer. Bioessays 14:33–36 (1992).
T. C. Brown and J. Jiricny. Different base/base mispairs are corrected with different efficiencies and specificities in monkey kidney cells. Cell 54:972–976 (1988).
A. S. Yang, J.-C. Shen, J.-M. Zingg, S. Mi, and P. A. Jones. HhaI and HpaII DNA methyltransferase bind DNA mismatches, methylate uracil, and block DNA repair. Nucleic Acids Res. 23:1380–1387 (1995).
J. C. Wu and D. V. Santi. On the mechanism and inhibition of DNA cytosine methyltransferases. In Biochemistry and Biology of DNA methylation. Prog. Clin. Biol. Res. 198, New York, Liss, pp 119–129.
J. C. Shen, W. M. Rideout, and P. A. Jones. High frequency of mutagenesis by a DNA methyltransferase. Cell 71:1073–1080 (1992).
B. Bandaru, M. Wyszynski, and A. S. Bhagwat. HpaII methyltransferase is mutagenic in Escherichia coli. J. Bacteriol. 177:2950–2952 (1995).
M. Wyszynski, S. Gabbara, and A. S. Bhagwat. Cytosine deaminations catalyzed by DNA cytosine methyltransferases are unlikely to be the major cause of mutational hot spots at sites of cytosine methylation in Escherichia coli Proc. Natl. Acad. Sci. USA 91:1574–1578 (1994).
T. Lindahl and B. Nyberg. Heat-induced deamination of cytosine residues in Deoxyribonucleic Acid. Biochemistry 13:3405–3410 (1974).
M. M. Similie, R. Pascale, M. R. De Miglio, A. Nufris, L. Daino, M. A. Seddaiu, L. Gaspa, and F. Feo. Correlation between S-adenosyl-L-methionine content and production of c-myc, c-Haras, and c-Ki-ras mRNA transcripts in the early stages of rat liver carcinogenesis. Cancer Lett. 79:9–16 (1994).
G. Varela-Moreiras, C. Ragel, and J. Perez de Miguelsanz. Choline deficiency and methotrexate treatment induces marked but reversible changes in hepatic folate concentrations, serum homocysteine, and DNA methylation rates in rats. J. Am. Coll. Nutr. 14:480–485 (1995).
N. Shivapurkar and L. A. Poirier. Tissue levels of S-Adenosylmethionine and S-Adenosylhomocysteine in rats fed methyl-deficient, amino acid-defined diets for one to five weeks. Carcinogenesis 4:1051–1057 (1983).
J. K. Christman, G. Sheikhnejad, M. Dizik, S. Abileah, and E. Wainfan. Reversibility of changes in nucleic acid methylation and gene expression induced in rat liver by severe dietary methyl deficiency. Carcinogenesis 14:551–557 (1993).
E. Giovannucci, M. J. Stampfer, G. A. Colditz, E. B. Rimm, D. Trichopoulos, B. A. Rosner, F. E. Speizer, and W. C. Willett. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J. Natl. Cancer Inst. 85:875–884 (1993).
J.-M. Zingg, J. C. Shen, A. S. Yang, H. Rapoport, and P. A. Jones. Methylation inhibitors can increase the rate of cytosine deamination by (cytosine-5)-DNA methyltransferase. Nucleic Acids Res. 24:3267–3276 (1996).
L. Jackson-Grusby, P. W. Laird, S. N. Magge, B. J. Moeller, and R. Jaenisch. Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc. Natl. Acad. Sci. USA 94:4681–4685 (1997).
D. Santi, G. Garrett, and P. J. Barr. On the mechanism of inhibition of DNA cytosine methyltransferases by cytosine analogs. Cell 33:9–10 (1983).
X. Cheng. Structure and function of DNA methyltransferases. Annu. Rev. Biohys. Struct. 24:293–318 (1995).
S. Kumar, X. Cheng, S. Klimasauskas, S. Mi, J. Postafi, R. J. Roberts, and G. G. Wilson. The DNA (cytosine-5) methyltransferases. Nucleic Acids Res. 22:1–10 (1994).
W. M. Rideout III, G. A. Coetzee, A. F. Olumi, and P. A. Jones. 5-methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 249:1288–1290 (1990).
M. S. Greenblatt, W. P. Bennett, M. Hollstein, and C. C. Harris. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855–4878 (1994).
A. N. Magewu and P. A. Jones. Ubiquitous and tenacious methylation of the CpG site in codon 248 of the p53 gene may explain its frequent appearance as a mutational hotspot in human cancer. Mol. Cell Biol. 14:4225–4232 (1994).
S. P. Tornaletti and G. P. Pfeifer. Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers. Oncogene 10:1493–1499 (1995).
M. F. Denissenko, J. X. Chen, M. S. Tang, and G. P. Pfeifer. Cytosine methylation determines hot spots for DNA damage in the human p53 gene. Proc. Natl. Acad. Sci. USA 94:3893–3898 (1997).
M. F. Denissenko, A. Pao, M. S. Tang, and G. P. Pfeifer. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hot spots in p53. Science 274:430–432 (1996).
M. L. Gonzalgo and P. A. Jones. Mutagenic and epigenetic effects of DNA methylation. Mutation Res. 386:107–118 (1997).
T. Nobori, K. Miura, D. J. Wu, A. Lois, K. Takabayashi, and D. A. Carson. Deletions of the cyclin-dependent kinase 4-inhibitor gene in multiple human cancers. Nature 368:753–756 (1994).
A. P. Feinberg, C. W. Gehrke, K. C. Kuo, and M. Ehrlich. Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res. 48:1159–1161 (1988).
S. B. Baylin, E. R. Fearon, B. Vogelstein, A. de Bustros, S. J. Sharks, P. J. Burke, S. P. Staal, and D. Nelkin. Hypermethylation of the 5′ region of the calcitonin gene is a property of human lymphoid and myeloid malignancies. Blood 70:412–417 (1987).
R. Stein, A. Razin, and H. Cedar. In vitro methylation of the hamster adenine phosphorybosyltransferase gene inhibits its expression in mouse L cells. Proc. Natl. Acad. Sci. USA 79:3418–3422 (1982).
L. Vardinon, A. Kressmann, H. Cedar, M. Maechler, and W. Doerfler. Expression of a cloned adenovirus gene is inhibited by in vitro methylation. Proc. Natl. Acad. Sci. USA 79:1073–1077 (1982).
R. R. Meehan, J. P. Lewis, S. Mc Kay, E. L. Kleiner, and A. P. Bird. Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell 58:499–507 (1989).
P. H. Tate and A. Bird. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr. Biol. 3:226–231 (1993).
H. Cedar. DNA methylation and gene activity. Cell 53:3–4 (1988).
A. P. Bird. The essentials of DNA methylation. Cell 70:5–8 (1992).
T. L. Kautiainen and P. A. Jones. DNA methyltransferase levels in tumorigenic and nontumorigeneic cells in culture. J. Biol. Chem. 261:1594–1598 (1986).
V. Greger, E. Passarge, W. Hopping, E. Messmer, and B. Horsethmke. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum. Genet 83:155–158 (1989).
T. Sakai, J. Togushida, N. Ohtani, D. W. Yandell, J. Rapaport, and T. P. Dryja. Allele-specific hypermethylation of the retinoblastoma tumor suppressor gene. Am. Hum. Genet. 48:880–888 (1991).
J. G. Herman, F. Latif, Y. Weng, M. I. Lerman, B. Zbar, S. Liu, D. Samid, D-S Duan, J. R. Gnarra, W. M. Linehan, and S. B. Baylin. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA 91:9700–9704 (1994).
Y. L. Ottaviano, J. P. Issa, F. F. Park, H. S. Smith, S. B. Baylin, and N. E. Davidson. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54:2552–2555 (1994).
A. T. Ferguson, R. G. Lapidus, S. B. Baylin, and N. E. Davidson. Demethylation of the estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res. 55:2279–2283 (1995).
J. P. Issa, B. A. Zenbauer, C. J. Civin, M. I. Collector, S. J. Sharkis, N. E. Davidson, S. H. Kaufman, and S. B. Baylin. The estrogen receptor CpG island is methylated in most hematopoetic neoplasms. Cancer Res. 56:973–977 (1996).
J. P. Issa, Y. L. Ottaviano, P. Celano, S. R. Hamilton, N. E. Davidson, and S. B. Baylin. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat. Genet. 7:536–540 (1994).
J. P. Issa, S. B. Baylin, and S. A. Belinsky. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res. 56:3655–3658 (1996).
K. Yoshiura, Y. Kanai, A. Ochiai, Y. Shimoyama, T. Sugimura, and S. Hirohashi. Silencing of the E-Cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc. Natl. Acad. Sci. USA 92:7416–7419 (1995).
R. Hahnel, J. Harvey, and P. Kay. Hypermethylation of the myogeneic gene Myf-3 in human breast carcinomas. Anticancer Res. 16:2111–2115 (1996).
J. G. Herman, J. Jen, A. Merlo, and S. B. Baylin. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15/INK4B. Cancer Res. 56:722–727 (1996).
J. G. Herman, L. Mao, D. J. Lee, E. Gabrielson, P. C. Burger, S. B. Baylin, and D. Sidransky. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/MTS1 in human cancers. Nature Med. 1:686–692 (1995).
J. G. Herman, A. Merlo, L. Mao, R. G. Lapidus, J. P. Issa, N. E. Davidson, D. Sidransky, and S. B. Baylin. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:4525–4530 (1995).
M. Gonzalez-Zulueta, C. M. Bender, A. S. Yang, T. Nguyen, R. W. Beart, J. M. Van Tornout, and P. A. Jones. Methylation of the 5′ CpG island of the p16 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55:4531–4535 (1995).
J. F. Costello, M. S. Berger, H-T Huang, and W. K. Cavenee. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res. 56:2405–2410 (1996).
K. W. Lo, S.-T. Cheung, Aran Hasselt, Y. S. Tsang, K. F. Mak, Y. F. Cheng, K. K. S. Woo, J. C. K. Lee, and D. P. Huang. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res. 56:2721–2725 (1996).
Y. Zhang, T. Shields, T. Crenshaw, Y. Hao, T. Moulton, and B. Tycko. Imprinting of human H19: allele-specific CpG methylation, loss of the active allele in Wilms' tumor and potential for somatic allele switching. Am. J. Hum. Genet. 53:113–124 (1993).
J. B. Nelson, W.-L. Lo, S. H. Nguyen, D. F. Jarrad, J. D. Brooks, S. R. Magnuson, T. J. Opgenorth, W. G. Nelson, and S. G. Bova. Methylation of the 5′ CpG island of the Endothelin B receptor gene is common in human prostate cancer. Cancer Res. 57:35–37 (1997).
M. Zion, D. Ben Yehuda, A. Avraham, O. Cohen, M. Wetzler, D. Melloul, and Y. Ben Neriah. Progressive de novo methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc. Natl. Acad. Sci. USA 91:10722–10726 (1994).
A. Dobrovic and D. Simpfendorfer. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 57:3347–3350 (1997).
S. B. Baylin, M. Makos, J. Wu, R.-W. C. Yen, A. deBustros, P. Vertino, and B. D. Nelkin. Abnormal patterns of DNA methylation in human neoplasia: potential consequences for tumor progression. Cancer Cells 3:383–390 (1991).
P. A. Jones. DNA methylation errors and cancer. Cancer Res. 56:2463–2467 (1996).
P. A. Jones, M. J. Wolkowicz, W. M. Rideout, F. G. Gonzales, C. M. Marziasz, G. A. Coetzee, and S. J. Tapscott. De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines. Proc. Natl. Acad. Sci. USA 87:6117–6121 (1990).
F. Antequera, J. Boyes, and A. Bird. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell 62:503–514 (1990).
A. G. Knudson. Hereditary cancers of man. Cancer Inv. 1:187–193 (1983).
T. Ushijima, K. Morimura, Y. Hosoya, H. Okonogi, M. Tatematsu, T. Sugimura, and M. Nagao. Proc. Natl. Acad. Sci. USA 94:2284–2289 (1997).
M. Schmid, D. Grunert, T. Haaf, and W. Engel. A direct demonstration of somatically paired heterochromatin of human chromosomes. Cytogenet. Cell. Genet. 36:554–561 (1983).
M. Schmid, T. Haaf, and D. Grunert. 5-Azacytidine-induced under-condensation in human chromosomes. Hum. Genet. 67:257–263 (1984).
P. A. Jones and S. M. Taylor. Cellular differentiation, cytidine analogs, and DNA methylation. Cell 20:85–93 (1980).
C. Taylor, K. Ford, B. A. Connolly, and D. P. Hornby. Determination of the order of substrate addition to MspI DNA methytransferase using a novel mechanism-based inhibitor. Biochem. J. 291:493–504 (1993).
A. R. MacLeod and M. Szyf. Expression of antisense to DNA methyltransferase mRNA induces DNA demethylation and inhibits tumorigenesis. J. Biol. Chem. 270:8037–8043 (1995).
S. Ramchandani, A. R. MacLeod, M. Pinard, E. von Hofe, and M. Szyf. Inhibition of tumorigenesis by a cytosine-DNA methyltransferase antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 94:684–689 (1997).
S. F. De Cabo, J. Santos, and J. Fernandez Piqueras. Molecular and cytological evidence of S-adenosyl-L-homocysteine as an innocuous undermethylating agent in vivo. Cytogenet. Cell Genet. 71:187–192 (1995).
R. T. Borchardt. S-Adenosyl-L-methionone-Dependent Macromolecule Methyltransferases: Potential targets for the design of chemotherapeutic agents. J. Med. Chem. 23:347–356 (1980).
W. K. Long, G. E. Fronko, R. G. Lindmeyer, B. Wu, and E. E. Henderson. Effects of S-Adenosylhomocysteine and analogs on Epstein-Barr virus-induced transformation, expression of the Epstein Barr virus capsid antigen, and methylation of Epstein Barr virus DNA. J. Virol. 61:221–224 (1987).
P. Blanchard, N. Dodic, J. L. Fourrey, F. Lawrence, A. M. Mouna, and M. Robert-Gero. Synthesis and biological activity of sinefungin analogues. J. Med. Chem. 34:2798–2803 (1991).
K. Shinkai, M. Mukai, T. Horai, H. Ohigashi, S. Nishikawa, H. Inoue, Y. Takeda, and H. Akedo. Inhibition of in vitro tumor cell invasion by transmethylation inhibitors. Jpn. J. Cancer Res. 80:716–719 (1989).
D. M. Woodcock, J. K. Adams, R. G. Allan, and I. A. Cooper. Effect of several inhibitors of enzymatic DNA methylation on the in vivo methylation of different classes of DNA sequences in a cultured human cell line. Nucleic Acids Res. 11:489–499 (1983).
G. V. Moreiras, C. Ragel, and J. Perez de Miguelsanz. Choline deficiency and methotrexate treatment induces marked but reversible changes in hepatic folate concentrations, serum homocysteine, and DNA methylation rates in rats. J. Am. Coll. Nutr. 14:480–485 (1995).
J. Nyce. Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res. 49:5829–5836 (1989).
D. L. Kramer, C. W. Porter, R. T. Borchardt, and J. R. Sufrin. Combined modulation of S-adenosylmethionine biosynthesis and S-adenosylhomocysteine metabolism enhances inhibition of nucleic acid methylation and L1210 cell growth. Cancer Res. 50:3838–3842 (1990).
J. K. Christman, P. Price, L. Pedrinan, and G. Acs. Correlation between hypomethylation of DNA and expression of globin genes in Friend erythroleukemia cells. Eur. J. Biochem. 81:53–61 (1977).
T. A. Bestor, S. B. Hellewell, and V. M. Ingram. Differentiation of two mouse cell lines is associated with hypomethylation of their genomes. Mol. Cell Biol. 4:1800–1806 (1984).
G. A. Miura, R. K. Gordon, J. A. Montgomery, and P. K. Chiang. 4′-Thioadenosine as a novel inhibitor of S-adenosyl homocysteine hydrolase and an inducer for the differentiation of HL-60 human leukemia cells. Adv. Exp. Med. Biol. 195:667–672 (1986).
J. Aarbakke, G. A. Miura, P. S. Prytz, A. Bessesen, L. Sirdal, R. K. Gordon, and P. K. Chiang. Induction of HL-60 cell differentiation by 3-deaza-(+)-aristeromycin, an inhibitor of S-adenosylhomocysteine hydrolase. Cancer Res. 46:5469–5492 (1988).
O. Heby. DNA methylation and polyamines in embryonic-development and cancer. Int. J. Dev. Biol. 39:737–757 (1995).
C. W. Porter and J. R. Sufrin. Interference with polyamine biosynthesis and/or function by analogs of polyamines or methionine as a potential anticancer chemotherapeutic strategy. Anticancer. Res. 6:525–542 (1986).
A. E. Pegg and R. P. McCann. S-Adenosylmethionine decarboxylase as an enzyme target for therapy. Pharmacol. Ther. 56:369–377 (1992).
K. Lertratanangkoon, R. S. Orkiszewski, and J. M. Scimeca. Methyl-donor deficiency due to chemically induced glutathione depletion. Cancer Res. 56:995–1005 (1996).
J. Quddus, K. J. Johnson, J. Gavalchin, E. P. Amento, C. E. Chrisp, R. L. Yung, and B. C. Richardson. Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J. Clin. Invest. 92:38–53 (1993).
J. L. Counts, J. I. Sarmiento, M. L. Harbison, J. C. Downing, R. M. McClain, and J. I. Goodman. Cell proliferation and global methylation status changes in mouse liver after phenobarbital and/or choline-devoid, methionine-deficient diet administration. Carcinogenesis 17:1251–1257 (1996).
A. Piskala and F. Sorm. Nucleic acids components and their analogs. Synthesis of L-glycosyl derivatives of 5-azauracil and 5-azacytosine. Coll. Czech. Chem. Commun. 29:2060–2067 (1964).
P. Pithova, A. Piskala, and J. Pitha. Nucleic acid components and their analogs. LXVI Hydrolysis of 5-azacytidine and its connection with biological activity. Collect. Czech. Chem. Commun. 30:2801–2811 (1965).
H. Burchenal, K. Ciovacco, K. Kalaher, T. O'Toole, R. Keifner, M. D. Dowling, C. K. Chu, K. Watanabe, I. Wempen, and J. J. Fox. Antileukemic effects of pseudoisocytidine, a new synthetic Pyrimidine C-Nucleoside. Cancer Res. 36:1520–1523 (1978).
D. D. Von Hoff, M. Slavik, and F. M. Muggia. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann. Int. Med. 85:237–245 (1976).
G. E. Rivard, R. L. Momparler, J. Demers, P. Benoit, R. Raymond, K. T. Lin, and L. F. Momparler. Phase I study on 5-Aza-2′-deoxycytidine in children with acute leukemia. Leukemia Res. 5:453–462 (1981).
R. L. Momparler, G. E. Rivard, and M. Gygner. Clinical trial on 5-Aza-2′-deoxycytidine in patients with acute leukemia. Pharmacop. Ther. 30:277–286 (1985).
S. M. Taylor and P. A. Jones. Mechanism of action of eukaryotic DNA methyltransferase: Use of 5-Azacytosine containing DNA. J. Mol. Bio. 162:679–692 (1982).
S. Friedman. The irreversible binding of azacytosine-containing DNA fragments to bacterial DNA (cytosine-5) methyltransferase. Nucleic Acids Res. 260:5698–5705 (1985).
S. Klimasauskas, S. Kumar, R. J. Roberts, and X. Cheng. HhaI methyltransferase flips its target base out of the DNA helix. Cell 76:357–369 (1994).
P. A. Jones and S. M. Taylor. Hemimethylated duplex DNAs prepared from 5-azacytidine treated cells. Nucleic Acids Res. 162:679–692 (1981).
R. L. Momparler and D. Derse. Kinetics of phosphorylation of 5-Aza-2′-deoxycytidine by deoxycytidine kinase. Biochem. Pharmacol. 28:1443–1444 (1979).
S. Gabarra and A. S. Bhagwat. The mechanism of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. Biochem. J. 307:87–92 (1995).
T. Lee, M. Karon, and R. L. Momparler. Kinetic studies in phosphorylation of 5-Azacytidine with purified uridine-cytidine kinase from calf thymus. Cancer Res. 34:3482–3488 (1974).
R. L. Momparler, S. Siegel, F. Avila, and T. Lee. Effect of tRNA from 5-Azacytidine treated hamster fibrosarcoma cells on in vitro protein synthesis in a cell-free system. Biochem. Pharmacol. 25:389–392 (1976).
R. L. Momparler and Joel Goodman. In vitro cytotoxic and biochemical effects of 5-Aza-2′-deoxycytidine. Cancer Res. 37:1636–1639 (1977).
R. Juttermann, E. Li, and R. Jaenisch. Toxicity of 5′-Aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than by DNA hypomethylation. Proc. Natl. Acad. Sci. USA 91:11797–11801 (1994).
L. H. Li, E. J. Olin, H. H. Buskirk, and L. M. Reinke. Cytotoxicity and mode of action of 5-Azacytidine on L1210 leukemia. Cancer Res. 36:2760–2769 (1970).
R. L. Momparler, J. Samson, L. F. Momparler, and G. E. Rivard. Cell cycle effects and cellular pharmacology of 5-aza-2′-deoxycytidine. Cancer Chemother. Pharmac. 13:191–194 (1984).
M. Karon, L. Sieger, S. Leimbrock, J. Z. Finkelstein, M. E. Nesbit, and J. Swaney. 5-Azacytidine: A new active agent for the treatment of acute leukemia. Blood 42:359–365 (1973).
L. A. Michalowsky and P. A. Jones. Differential nuclear protein binding to 5-Azacytosine-containing DNA as a potential mechanism for 5-Aza-2′-deoxycytidine resistance. Mol. Cell. Biol. 7:3076–3083 (1987).
P. W. Laird, L. Jackson-Grusby, A. Fazeli, S. L. Dickenson, W. E. Jung, E. Li, R. A. Weinberg, and R. Jaenisch. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81:197–205 (1995).
S. M. Taylor and P. A. Jones. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell 17:777–779 (1979).
F. Creusot, G. Acs, and J. K. Christman. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-Aza-2′-deoxycytidine. J. Biol. Chem. 257:2041–2048 (1982).
E. J. Freirich, G. P. Bodey, J. E. Harris, and J. S. Hart. Therapy for acute granulocytic leukemia. Cancer Res. 27:2573–2578 (1962).
A. Pinto and V. Zagonel. 5-Aza-2′-deoxycytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present, and future trends. Leukemia 7:51–60 (1993).
A. E. Pegg, J. A. Secrist, and R. Madhubala. Properties of L1210 cells resistant to alpha-difluoromethylornithine. Cancer Res. 48:759–774 (1988).
J. Janne, L. Alhonen, and P. Leinonen. Polyamines: from molecular biology to clinical applications. Ann. Med. 23:241–259 (1991).
P. K. Chiang, R. K. Gordon, J. Tal, G. C. Zeng, B. P. Doctor, K. Pardhasaradhi, and P. P. McCann. S-Adenosylmethionine and methylation. FASEB J. 10:471–480 (1996).
J. B. Lombardini, A. W. Coulter, and P. Talalay. Analogues of methionine as substrates and inhibitors of the methionine adenosyltransferase reaction. Mol. Pharmacol. 6:481–499 (1970).
A. W. Coulter, J. B. Lombardini, and P. Talalay. Structural and conformational analogues of L-methionine as inhibitors of the enzymatic synthesis of S-Adenosyl-L-methionine I. Saturated and unsaturated aliphatic amino acids. Mol. Pharmacol. 10:293–304 (1974).
A. W. Coulter, J. B. Lombardini, and P. Talalay. Structural and conformational analogues of L-methionine as inhibitors of the enzymatic synthesis of S-Adenosyl-L-methionine II. Aromatic amino acids. Mol. Pharmacol. 10:305–318 (1974).
A. W. Coulter, J. B. Lombardini, and P. Talalay. Structural and conformational analogues of L-methionine as inhibitors of the enzymatic synthesis of S-Adenosyl-L-methionine III. Carboxylic and heterocyclic amino acids. Mol. Pharmacol. 10:319–331 (1974).
J. R. Sufrin, A. W. Coulter, and P. Talalay. Structural and conformational analogues of L-methionine as inhibitors of the enzymatic synthesis of S-Adenosyl-L-methionine IV. Further mono-bi-and tricyclic amino acids. Mol. Pharmacol. 15:661–677 (1979).
F. Schlenk, C. H. Hanuum, and A. J. Ferro. Arch. Biochem. Biophys. 187–194 (1978).
J.-M. Zingg and P. A. Jones. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 18:101–114 (1997).
E. De Clercq. S-Adenosylhomocysteine hydrolase inhibitors as broadspectrum antiviral agents. Biochem. Pharmacol. 36:2567–2575 (1987).
C. M. Bender, M. M. Pao, and P. A. Jones. Inhibition of DNA methylation by 5-Aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 58:95–101 (1998).
R. L. Momparler. Molecular, cellular, and animal pharmacology of 5-aza-2′-deoxycytidine. Pharmacop. Ther. 30:287–299 (1985).
R. L. Momparler and D. M. Fambrough. Molecular forms of chicken embryo aetylcholineesterase in vitro and in vivo. Isolation and characterization. J. Biol. Chem. 254:4790–4799 (1979).
R. L. Momparler, J. Veseley, L. F. Momparler, and G. E. Rivard. Synergistic action of 5-aza-2′-deoxycytidine and 3-deazauridine on L1210 leukemia cells and EMT6 tumor cells. Cancer Res. 39:3822–3827 (1979).
A. W. Harris, E. C. Reynolds, and L. R. Finch. Effect of thymidine on the sensitivity of cultured mouse tumor cells to 1-B-arabinofuranosylcytosine. Cancer Res. 39:538–541 (1979).
B. R. de Saint-Vincent, M. Dechamps, and G. Buttin. The modulation of the thymidine triphosphate pool of chinese hamster cells by dCMP deaminase and UDP reductase: thymidine auxotrophy induced by CTP in dCMP deaminase-deficient line. J. Biol. Chem. 255:162–167 (1980).
E. C. Moore and R. B. Hurlbert. Regulation of mammalian deoxyribonucleotide biosynthesis by nucleotides as activators and inhibitors. J. Biol. Chem. 241:4802–4809 (1966).
F. G. Scarano, G. Geraci, and M. Rossi. Deoxycytidylate aminohydrase. II. Kinetic properties. The activatory effect of deoxycytidine triphosphate and the inhibitory effect of deoxythymidine triphosphate. Biochemistry 6:192–201 (1967).
R. L. Momparler and N. Onetto. Drug resistance to cytosine arabinoside. In D. Kessel (ed.). Resistance to Antineoplastic drugs, CRC press, Boca Raton, 1988, pp 354–367.
R. L. Momparler and L. F. Momparler. Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-Aza-2′-deoxycytidine and 3-deazauridine. Cancer Chemother. Pharmacol. 25:51–54 (1989).
R. L. Momparler, S. Cote, and N. Eliopoulos. Pharmacological approach for optimization of the dose schedule of 5-Aza-2′-deoxycytidine (Decitabine) for the therapy of leukemia. Leukemia 11:175–180 (1997).
K. T. Lin, R. L. Momparler, and G. E. Rivard. High performance liquid chromatographic analysis of chemical stability of 5-Aza-2′-deoxycytidine. J. Pharm. Disc. 70:1228–1232 (1981).
E. J. Freireich. Effect of schedule and combinations on clinical effectiveness of ARA-C in adult acute leukemia. Med. Pediatric. Oncol. 1:169–172 (1982).
H. E. Skipper, F. M. Schabel, L. G. Mellet, J. A. Montgomery, L. J. Wukoff, H. H. Lloyd, and R. W. Brockman. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationship of optimal dose schedules. Cancer Chemother. 54:431–450 (1970).
R. L. Momparler, J. Bouchard, N. Onetto, and G. E. Rivard. 5-Aza-2′-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation. Leukemia Res. 8:181–185 (1984).
R. L. Momparler, J. K. Vesely, L. F. Momparler, and G. E. Rivard. Synergistic action of 5-Aza-2′-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT tumor cells. Cancer Res. 39:3822–3827 (1979).
D. Y. Bouffard, L. F. Momparler, and R. L. Momparler. Enhancement of the antileukemic activity of 5-Aza-2′-deoxycytidine by cyclopentyl cytosine in the HL-60 leukemic cell line. Ani-Cancer Drugs 5:223–228 (1994).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bender, C.M., Zingg, JM. & Jones, P.A. DNA Methylation as a Target for Drug Design. Pharm Res 15, 175–187 (1998). https://doi.org/10.1023/A:1011946030404
Issue Date:
DOI: https://doi.org/10.1023/A:1011946030404